Genetic markers: Genes involved in thrombosis

Journal of Cardiovascular Risk

Volumn 4, Issue 5, 1997, Pages 347-352

  Wu, Kenneth K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute myocardial infarction; Antithrombin III; Factor V Leiden; Factor VII; Fibrinogen; Plasminogen activator inhibitor 1; Protein C; Protein S; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; GLYCOPROTEIN IIIA; HOMOCYSTEINE; LEUCINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLINE; PROTEIN C; PROTEIN S;

GENETIC MARKER; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

EID: 0031417169     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043798-199710000-00005     Document Type: Article

References (44)

1. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993, 90:1004-1008.
2. Dahlback B, Hildebrand B: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994, 91:1396-1400.
3. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
4. Dahlback B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995, 85:607-614.
5. Plutzky J, Hoskins JH, Long GL, Crabtree GR: Evolution and organization of the human protein C gene. Proc Natl Acad Sci USA 1986, 83:546-560.
6. Long GL, Marshall A, Gardner JC, Naylor SL: Genes for vitamin Independent plasma protein C and S are located on chromosome 2 and 3, respectively. Somat Cell Mol Genet 1988, 14:93-97.
7. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68:1370-1373.
8. Reitsam PH, Poort SR, Bernard F, Gandrille S, Long GL, Sala N, et al.: Protein C deficiency: a database of mutations. Thromb Haemost 1993, 69:77-84.
9. Miletich JP, Sherman L, Broze GJ Jr: Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987, 317:991-994.
10. Hirsh J, Prins MH, Samama M: Approach to thrombophilia patients. In Hemostasis and Thrombosis, Third Edition. Edited by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: J.B. Lippincott Co.; 1994:1543-1561.
11. Ploos van Amstel HK, Reitsma PH, van der Logt CPE, Bertina RM: Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS β: duplication and silencing during primate evolution. Biochem 1990, 29:7853-7861.
12. Winter JH, Bennett B, Watt JL, Brown T, San Román C, Schinzel A, et al.: Genetic mapping of the structural gene for antithrombin III and Duffy Blood group and assignment of AT-III to 1 q22-q25. Ann Hum Genet 1982, 46:29-34.
13. Prochowni KEV, Bock SC, Orkin SH: Intron structure of the human AT-III gene differs from that of other members of the serine protease inhibitor superfamily. J Biol Chem 1985, 260:9608-9612.
14. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965, 13:516.
15. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, et al.: Antithrombin III mutation database: first update. Thromb Haemost 1993, 70:361-369.
16. Tait RC, Walker ID, Perry DJ, Carrell RW, Islam SIA, McCall F, et al.: Prevalence of antithrombin III deficiency in 4000 healthy blood donors [abstract]. Thromb Haemost 1991, 65:839.
17. Brenner B, Zivelin A, Lanir H, Greengard JS, Griffin JH, Seligsohn U: Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficiency newborn with massive thrombosis. Blood 1996, 88:877-880.
18. Trip MD, Cats VM, van Capelle FJ, Vreeken J: Platelet hyperaggregability and prognosis in survivors of myocardial infarction. N Engl J Med 1990, 323:1549-1554.
19. Wu KK: Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996, 239:17-34.
20. Meade TW, Mellows S, Brtozovic M, Miller GJ, Chakrabarti RR, North WR, et al.: Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986, ii:533-537.
21. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infraction. N Engl J Med 1984, 311:501-505.
22. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB: Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987, 258:1183-1186.
23. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J: Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994, 14:54-59.
24. Folsom AR, Wu KK, Shahar E, Davis CE: Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993, 13:1829-1836.
25. Bray PF, Barsh G, Rosa JP, Luo XY, Magenis E, Shuman MA: Physical linkage of the genes for platelet membrane glycoproteins llb and ill, Proc Natl Acad Sci USA 1988, 85:8683-8687. '
26. Newman PJ, Valentin N: Human platelet alloantigens: recent findings, new perspectives. Thromb Haemost 1995, 74:234-239.
27. Weiss Ebray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, et al: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996, 334:1090-1094.
28. Olarsen B, Teisberg P, Gedde-Dahl T Jr: Fibrinogen γ chain locus on chromosome 4 in man. Hum Genet 1982, 61:24-26.
29. Kant JA, Fornace AJ Jr, Saxe D, Simon Ml, McBride OW, Crabtree GR: Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985, 82:2344-2348.
30. Roy S, Overton O, Redman C: Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chains. J Biol Chem 1994, 269:691-695.
31. Baumann RE, Henschen AH: Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions Aa312 and Bβ448. Blood 1993, 82:2117-2124.
32. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987, i:1452-1455.
33. Thomas AE, Green FR, Kelleher CH, Wilkes PJ, Meade TW, Humphries SE: Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991, 65:487-490.
34. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al.: β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996, 93:440-449.
35. O’Hara PJ, Grant FJ, Haldeman BA: Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987, 84:5158-5162.
36. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S: A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991, 11:540-546.
37. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, et al.: Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vas Biol 1996, 16:72-76.
38. Silveira A, Green F, Karpe F, Blombäck MM, Humphries S, Hamsten A: Elevated levels of factor VII activity in the postprandial state: effect of factor V arg-gln polymorphism. Thromb Haemost 1994, 72:734-739.
39. Rosma PJ, van den Berg EA, Kooistra T: Human PAI-1 gene. J BioI Chem 1988, 263:9129-9141.
40. Hamsten A, Wiman B, de Faire U, Blombsck M: Increased plasma levels of a repaid inhibitor of PAI-1 in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557-1563.
41. Dawson S, Hamsten A, Wiman B, Henny A, Humphries SE: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of PAI-1 activity. Atheroscler Thromb 1991, 11:183-190.
42. Eriksson P, Kallin B, Van’t Hooft FM, Blivenholm P, Hamsten A: Allele specific increase in basal transcription of the PAI-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855.
43. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al.: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM Study. Thromb Haemost 1995, 74:837-841.
44. Malinow MR: Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990, 81:2004-2006.